This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
VISION Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
PSMA PET Imaging
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
Centers of Excellence
Urologic Oncology
Left Group
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Petros Grivas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Kidney Cancer Today
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Alicia Morgans, MD, MPH
nmCRPC
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular, Penile, and Rare GU Malignancies
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Education
Covid-19
The Prostate Cancer Foundation
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Pelvic Health & Reconstruction
Endourology
Testicular Cancer
Clinical Trials
From the Editor
Search Clinical Trials
Transformative Trials
DORA - PCCTC
IRONMAN - PCCTC
PROMISE - PCCTC
SPLASH Trial
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
RSNA 2022
SUO 2022
Urologists for Social Responsibility 2023
Upcoming
ASCO GU 2023
All Conferences
View All
PCF
UroToday Home
Conference Highlights
EAU 2017
EAU 2017
- Prostate Cancer
- Bladder Cancer
- Renal Cancer
- Endourology
- Testicular Cancer
EAU 2017 - Prostate Cancer
Viewing 1-20 of 87 articles
EAU 2017: State-of-the-art lecture Levels of competence in mpMRI reporting
EAU 2017: State-of-the-art lecture : What do urologists need to know about mpMRI targeted biopsy?
EAU 2017: Discussant: Is PIRADS 2.0 standardized enough?
EAU 2017: Reading and interpreting mpMRI: PIRADS 2.0
EAU 2017: European Society of Urogenital Radiology (ESUR) lecture PI-RADS in clinical practice including differential diagnoses in prostate imaging
EAU 2017: Metastases and death after 15 year of follow-up in men with screen-detected low-risk prostate cancer treated with protocol based active surveillance, radical prostatectomy or radiotherapy (804)
EAU 2017: MRI as a follow up tool in active surveillance: results from an MRI-defined active surveillance cohort
EAU 2017: Multiparametric MRI represents an added value but not a substitute of follow-up biopsies in patients on active surveillance for low-risk prostate cancer
EAU 2017: Pathological findings at radical prostatectomy after initial active surveillance in low-risk prostate cancer patients. Did we miss the chance to cure?
EAU 2017: PTEN status in diagnostic biopsies predicts active surveillance rebiopsy Gleason upgrade, treatment change and adverse surgical histopathological findings
EAU 2017: Variation in the use of active surveillance for low-risk prostate cancer
EAU 2017: Metastases and death after 15 year of follow-up in men with screen-detected low-risk prostate cancer treated with protocol based active surveillance, radical prostatectomy or radiotherapy
EAU 2017: MRI as a follow up tool in active surveillance – results from an MRI-defined active surveillance cohort (387 men, median 5 year follow up)
EAU 2017: Risk-based selection for active surveillance: Results of the Movember Foundation’s Global Action Plan prostate cancer active surveillance (GAP3) initiative
EAU 2017: Variation in the use of active surveillance for low-risk prostate cancer
EAU 2017: State-of-the-art Lecture: EAU Guidelines on mCRPC – An Update
EAU 2017: Is There a Role for Local Treatment of Oligometastatic Disease? No
EAU 2017: Is There a Role for Local Treatment of Oligometastatic Disease? Yes
EAU 2017: State-of-the-art lecture Hereditary Prostate Cancer
EAU 2017: Active Surveillance for 3+4=7 Prostate Cancer - Pro
1
2
3
4
5
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free